The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Significant breast development in transgender women begins within two to three months of the start of hormone therapy and continues for up to two years or more. Breast development seems to be better in transgender women who have a higher body mass index. This indicates that weight gain in the early phases of hormone therapy may be beneficial not only for fat distribution, but for breast development. Different estrogens, such as estradiol valerate, conjugated estrogens, and ethinylestradiol, appear to produce equivalent results in terms of breast sizes in transgender women. The sudden discontinuation of estrogen therapy has been associated with onset of galactorrhea (lactation). Breast, nipple, and areolar development varies considerably depending on genetics, nutrition, age of HRT initiation, and many other factors. Development can take a couple years to nearly a decade for some. However, many transgender women report there is often a "stall" in breast growth during transition, or significant breast asymmetry. Transgender women on HRT often experience less breast development than cisgender women (especially if started after young adulthood). For this reason, many seek breast augmentation. Transgender patients opting for breast reduction are rare. Shoulder width and the size of the rib cage also play a role in the perceivable size of the breasts; both are usually larger in transgender women, causing the breasts to appear proportionally smaller.
Aquileia is a comune (municipality) in the Friuli-Venezia Giulia region of northeastern Italy. It is situated at the head of the Adriatic at the edge of the lagoons, about 10 kilometres (6 mi) from the sea, on the river Natiso (modern Natisone), the course of which has changed somewhat since the Roman era. In classical antiquity, Aquileia was a major Roman city with an estimated population close to 100,000 in the 2nd century AD. Founded as a Roman military colony in 181 BC, Aquileia became the capital of the Augustan X region and a metropolitan center for early Christianity. During late antiquity, it was the first city in the Italian Peninsula to be sacked by Attila the Hun. Today, Aquileia is one of the most significant archaeological sites in northern Italy. Its ruins, including mosaics and an early Christian basilica, are a UNESCO World Heritage Site. Aquileia also holds historical importance as one of the former capitals of Friuli, with its coat of arms being the symbol of the region.
== Toxicity == Ingestion of lobeline may cause nausea, vomiting, diarrhea, coughing, dizziness, visual disturbances, hearing disturbances, mental confusion, weakness, slowed heart rate, increased blood pressure, increased breathing rate, tremors, and seizures. Lobeline has a narrow therapeutic index: the potentially beneficial dose of lobeline is very close to the toxic dose.
=== Effects === ACE inhibitors block the conversion of angiotensin I (ATI) to angiotensin II (ATII). Arteriolar resistance is lowered, venous capacity is increased; cardiac output, cardiac index, stroke work, and volume is lowered; resistance in renal blood vessels is lowered; and lead to increased natriuresis (excretion of sodium in the urine). Bradykinin levels increase because angiotensin-converting enzyme also degrades bradykinin, and its inhibition reduces bradykinin inactivation. Under normal conditions, angiotensin II has these effects:
=== Writing === Shonda Rhimes said in an interview that the fifth season will begin only a few days after the events in the fourth-season finale. She stated that the fifth season will see Olivia and Fitz the only people standing in a single piece, as she said "The world had been fairly blown apart for everybody except Olivia and Fitz. Everybody else was in a fairly blown apart place ... We pick up right there in that environment and we see what happens next." Rhimes continued talking about Cyrus and Mellie and their situation of not being in the White House anymore. Rhimes also confirmed that "the reconstitution" of Team OPA would happen in the fifth season, as Rhimes revealed in an interview with TVLine, as she explained that the Gladiator conceit was sidelined a bit in the fourth season to instead "healing" Olivia. She noted that "a lot of times it was just Huck and Quinn gladiating by themselves. And that wasn’t the same dynamic."
Sources: en.wikipedia.org
=== Climate === The climate of Jammu and Kashmir varies with altitude and across regions. Southern and southwestern areas have a sub-tropical climate, with hot summers and cool winters. This region receives most of its rainfall during the monsoon season. In the east and north, summers are usually pleasant. The effect of the monsoon diminishes in areas lying to the leeward side of the Pir Panjal, such as the Kashmir valley, and much of the rainfall happens in the spring season due to western disturbances. Winters are cold, with temperatures reaching sub-zero levels. Snowfall is common in the valley and the mountain areas.
In February 2015, the FDA reported about a transmission risk when people undergo a gastroenterology procedure called endoscopic retrograde cholangiopancreatography, where an endoscope enters the mouth, passes the stomach, and ends in the duodenum; if incompletely disinfected, the device can transmit CRE from one patient to another. The FDA's safety communication came a day after the UCLA Health System, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015. The FDA had issued its first notice about the devices in 2009.
=== Pathological mechanism === HLA-B27 is the most researched HLA-B allele due to its high relationship with spondyloarthropathies. Although it is not apparent how HLA-B27 promotes disease, theories exist and can be divided between antigen-dependent and antigen-independent categories.
Mahathir and Nelson Mandela shared a close relationship, forged during South Africa's struggle against apartheid. Malaysia played a crucial role in supporting South Africa's transition to democracy, particularly in its preparations for the historic 1994 election that saw Mandela elected as the country's first black president. Mahathir was the first international leader to visit Mandela following his release in 1990. During a meeting held at a Zambian government guest house, Mahathir presented Mandela with a silver keris, a symbol of Malaysia's constitutional monarchy system of government. Mandela visited Malaysia thrice during Mahathir's tenure as prime minister, first in 1990, second in 1993 and again in 1997. During his third visit, Mahathir hosted a private dinner for the South African president in Langkawi. The close relationship between the two leaders also benefited Malaysian businesses, granting them a "most favoured" status for securing contracts and business opportunities in South Africa. During Mandela's visit, Mahathir further strengthened this partnership with him by jointly launching the Malaysia-South Africa Business Council (MSABC) in Kuala Lumpur. The strong bilateral relations also led to significant progress in political and economic cooperation, with key agreements signed in trade, air services, and shipping. Additionally, Malaysia supported South Africa's development through scholarships for South African students and collaboration in science and technology.
== Nucleotide excision repair == As illustrated above, (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) forms bulky covalent DNA adducts with guanines. Most of these adducts can be efficiently eliminated from DNA by the process of nucleotide excision repair. Those adducts that are not removed can cause errors during DNA replication leading to carcinogenic mutations.
Sources: en.wikipedia.org
G banding Also Giemsa banding or G-banding. A technique used in cytogenetics to produce a visible karyotype by staining the condensed chromosomes with Giemsa stain. The staining produces consistent and identifiable patterns of dark and light "bands" in regions of chromatin, which allows specific chromosomes to be easily distinguished.
== Legislation == The plight of patients with rare diseases became an important political issue in the late 1970s and early 1980s. The US government was subject to pressure from activist groups such as NORD and many others. The chief sponsor of the bill (H.R. 5238) was Henry Waxman (sometimes referred to as the author of the Act), chairman of the Energy and Commerce Subcommittee on Health. It passed the House of Representatives on 14 December 1982, and was similarly approved by voice vote in the Senate on 17 December. On 4 January 1983, President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA. Market exclusivity is particularly appealing to pharmaceutical firms as an incentive to pursue orphan drug development.
To perform a manual white blood cell differential, the microscopist counts 100 cells on the blood smear and classifies them based on their appearance; sometimes 200 cells are counted. This gives the percentage of each type of white blood cell, and by multiplying these percentages by the total number of white blood cells, the absolute number of each type of white cell can be obtained. Manual counting is subject to sampling error because so few cells are counted compared with automated analysis, but it can identify abnormal cells that analyzers cannot, such as the blast cells seen in acute leukaemia. Clinically significant features like toxic granulation and vacuolation can also be ascertained from microscopic examination of white blood cells. The hematocrit can performed manually by filling a capillary tube with blood, centrifuging it, and measuring the percentage of the blood that consists of red blood cells. This is useful in some conditions that can cause automated hematocrit results to be incorrect, such as polycythemia (a highly elevated red blood cell count) or severe leukocytosis (a highly elevated white blood cell count, which interferes with red blood cell measurements by causing white blood cells to be counted as red cells).
Esters can be directly converted to nitriles. Methyl esters are often susceptible to decarboxylation in the Krapcho decarboxylation. Phenyl esters react to hydroxyarylketones in the Fries rearrangement. Specific esters are functionalized with an α-hydroxyl group in the Chan rearrangement. Esters with β-hydrogen atoms can be converted to alkenes in ester pyrolysis. Pairs of esters are coupled to give α-hydroxyketones in the acyloin condensation.
Therefore, the ban on said products was more a result of negative connotations towards its use and distribution by Chinese immigrants who were heavily persecuted during this particular period in history. As the 19th century progressed however, doctor Hamilton Wright worked to decrease the use of opium in the US by submitting the Harrison Act to congress. This act put taxes and restrictions on the sale and prescription of opium, as well as trying to stigmatize the opium poppy and its derivatives as "demon drugs", to try to scare people away from them. This act and the stigma of a demon drug on opium, led to the criminalization of people that used opium-based products. It made the use and possession of opium and any of its derivatives illegal. The restrictions were recently redefined by the Federal Controlled Substances Act of 1970.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.